Skip to content

ABOUT BIONOMICS

Bionomics is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need.

Ion channels serve as important mediators of physiological function in the CNS and the modulation of ion channels influences neurotransmission that leads to downstream signaling in the brain.

Utilizing our expertise in ion channel biology and translational medicine, we are developing orally active small molecule negative allosteric modulators (“NAMs”) and positive allosteric modulators (“PAMs”) of the α7 receptor to treat anxiety and stressor related disorders and cognitive dysfunction, respectively

Our goal is to be a leading biopharmaceutical company focused on the development and commercialization of novel, first-in-class treatments to transform the lives of patients with serious CNS disorders with high unmet medical need.